
RealRate

PHARMACEUTICAL 2018



Clovis Oncology Inc. Rank 177 of 349



RealRate

PHARMACEUTICAL 2018



Clovis Oncology Inc. Rank 177 of 349

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is -180%, being 98% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	626,940
Cost of Goods Sold	0
Intangible Assets	84,778
Liabilities, Current	81,517
Liabilities, Non-Current	0
Other Assets	19,505
Other Compr. Net Income	5,407
Other Expenses	8,159
Other Liabilities	286,077
Other Net Income	-112,344
Property and Equipment	4,007
Research and Development	142,498
Revenues	55,511
Selling, General and Administrative Expense	138,907

Output Variable	Value in 1000 USD
Assets	735,230
Liabilities	367,594
Expenses	289,564
Stockholders Equity	367,636
Net Income	-346,397
Comprehensive Net Income	-343,694
Economic Capital Ratio	-180%